



Faculty of Health Sciences 
Department of Medical Biology 
Expression and functional properties of selected 
miRNAs in human cancer tissue and cancer cell lines 
A study of expression and function of miR-143, miR-145 and miR-126 
in breast cancer and non-small cell lung cancer 
 
— 
Charles Walquist Johannessen 
A dissertation for the degree of Philosophiae Doctor – November 2018 
 
Expression and functional properties of selected miRNAs 
in human cancer tissue and cancer cell lines 
A study of expression and function of miR-143, miR-145 and miR-126 in breast cancer 
and non-small cell lung cancer 
 
Doctoral Thesis 











Translational Cancer Research Group 
Department of Medical Biology 
Faculty of Health Science 




The work presented in this thesis was carried out at the Translational Cancer Research Group, 
Department of Medical Biology, Faculty of Health Science, UiT – The Arctic University of 
Norway, Tromsø between 2014 and 2018. I would like to thank the Northern Norway Regional 
Health Authority for financing this work. 
First, I would like to express my deep gratitude to my main supervisor, Line Moi. Thank you 
for your inspired guidance, valuable suggestions, insightful criticism, encouragement and 
support throughout this thesis. Also, to my co-supervisor, professor Lill-Tove Rasmussen 
Busund, thank you for your invaluable and vast knowledge. Your expert advice has, no doubt, 
greatly improved the depth of my research. And to my co-supervisor, Yuri Kiselev, the person 
putting me on the path of science in the first place. Your enthusiasm, work ethics, rigorous 
attitude and dedication to scientific research has made a great impression on me, and I am sure 
it will continue to benefit my future life and career. 
I would also like to thank professor Eiliv Lund, together with the rest of the members of the 
Norwegian Women and Cancer study, for their good cooperation and support of my work. 
Thank you, Mona Irene Pedersen, for your excellent technical support, and kind and supporting 
words when I needed them. Thank you, Mehrdad Rakaee, my office partner and good friend. 
Our laughs and non-scientific discussions were always a welcome break, and highly valued. 
I would like to thank all my co-authors and fellow group members who have contributed to this 
work. It has been a privilege and pleasure to collaborate with, what I must consider, the best of 
the best. 
Thank you to my family and friends, especially May Wenche and Kristian. Your encouraging 
words during numerous coffee breaks and “fredagsgrøt” have been important motivators. 
Finally, to my beautiful wife and daughters. I am so incredible grateful for your unconditioned 









MicroRNAs (miRNAs) are small non-coding RNAs (ncRNAs) involved in the regulation of 
gene expression, and they are often seen dysregulated in cancer. For this reason, it is of great 
scientific interest to study these ncRNAs to better understand their distribution in human tissues 
and their mode of function. Based on a comprehensive miRNA microarray from 108 breast 
cancers in the Norwegian Woman and Cancer Study and 44 healthy controls, this thesis sought 
to investigate tissue expression and functional properties of the miRNA cluster miR-143/145 
in breast and lung cancer tissues and cell lines, as well as miR-126 in breast cancer (BC) tissue 
and cell lines. 
Our analysis found the miR-143/145 cluster to be downregulated in tumor samples from both 
breast and lung, as well as in their corresponding cancer cell lines. The transfection of miR-143 
into a number of cancer cell lines from both breast and lung, promoted proliferation in some, 
whilst having opposite or no effect in others. In contrast, all cell lines suffered inhibition in both 
proliferation and migration when transfected with miR-145. 
In BC tissue, expression of miR-143 and miR-145 was lower in malignant compared to benign 
breast tissue, and lower in the more aggressive tumors. Interestingly, miR-145 was mainly 
expressed in the myoepithelial cells of benign breast tissue, and at the subcellular level located 
to the nuclei. In lung cancer tissue, expression of the miR-143/145 cluster was found to correlate 
with expression of several sex steroid hormone receptors. Also, stromal expression of miR-143 
was an independent positive prognostic factor in female patients, whereas stromal expression 
of miR-145 was associated with improved disease specific survival for male patients. 
Both miR-126-3p and its passenger strand, miR-126-5p, was verified as downregulated in BCs 
as well as in all tested BC cell lines. The passenger strand had a strong proliferation promoting 
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effect in the most aggressive BC cell line, whilst having the opposite effect in the other cell 
lines. The introduction of miR-126-3p resulted in decreased proliferation and invasion in all 
BC cell lines. In BC tissue, expression of miR-126-5p was significantly higher in high grade 
tumors, and both miR-126 strands were downregulated in lymph node positive BCs when 
compared to tumors with no nodal involvement. 
This thesis depicts interesting findings, and contributes to a better understanding of context-
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1.1 Breast cancer 
Worldwide, there are reported more than 1.6 million new cases of breast cancer (BC) every 
year, and the annual BC death rate is in excess of 500.000 [1]. This makes BC the most 
diagnosed cancer in the female population, where it contributes to 25% of all new cancer cases, 
and 15% of all cancer related deaths [1]. The five year survival rate of BC is 89% [2], but once 
metastases to distant organs occur, the five year survival rate drops below 25% [3].  
Although metastatic BC rarely presents at the initial time of diagnosis, as many as 30% of 
patients diagnosed with early stage BC will later develop recurrent advanced disease or 
metastasis [4, 5]. The majority of BC metastases occur in the liver, bone, lung or central nervous 
system [6]. Although there has been some controversy regarding the effects of mammography 
[7], public screening programs are considered important for early detection and prevention of 
BC [8]. 
Figure 1: Anatomy and histology of the breast. Alvarado, 2016. 
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The mammary gland (figure 1) consists of several different cell types [9], and is a complex 
organ. The epithelial cells form the ductal network of the glands  which are bilayered structures 
comprised of luminal cells (milk secreting epithelial cells) and basal cells [10]. The luminal 
cells form the ducts and the secretory alveoli, and makes up the inner layer of the glands’ 
bilayered structure, whilst the basal cells form the outer layer which consists mainly of 
myoepithelial cells [10]. The function of the alveoli and the luminal cells is to secrete milk 
containing water and nutrients, whereas the contraction by the myoepithelial cells directs the 
milk through the ductal pathways [10, 11]. A relatively newly discovered cell type in this 
cellular landscape is the mammary stem cells which have been described as lineage-restricted  
cells with the capacity to differentiate into either luminal cells or myoepithelial cells [12, 13]. 
Precursor lesions of BC are annotated ductal carcinoma in situ (DCIS), and consist of clusters 
of neoplastic cells confined to the milk duct. It is estimated that up to 40% of DCIS cases 
progress into invasive carcinoma of no special type (NST), where cancer cells breach the 
basement membrane and infiltrate the surrounding tissue [14, 15]. Noteworthy, hereditary BC 
accounts for approximately 5-10% of all BC cases, and is primarily caused by mutations in one 
of the genes coding for the tumor suppressor proteins BRCA1 or BRCA2. Mutations in either 
of these genes are very potent cancer predictors, and women carrying these mutations have a 






BC is a highly heterogeneous disease composed of a diverse collection of molecular subtypes, 
which can be determined by gene expression patterns or immunohistochemistry (IHC) [18-21]. 
The identification of each tumor’s molecular subtype is of great value, as each subtype has 
biological and clinical features [20] which are associated with prognosis and direct choice of  
treatment [22]. It is established that the different gene expression patterns observed in BC 
account for this heterogeneity [19]. The histopathological features of BC include characteristics 
such as histological morphology, receptor status, tumor size, tumor grade and nodal 
involvement. With the knowledge of both the molecular subtype and the histopathological 
status, the metastatic predisposition of the primary tumor may be determined [22, 23]. With the 
access to whole-genome profiling, one has been able to categorize BC into four general 
molecular subtypes. These subtypes are the luminal A, luminal B, human epidermal growth 
factor receptor 2 positive (HER2+) and the triple-negative (TN)/basal-like (BL) BCs [19, 24, 
25]. Routinely, the classification of the tumors molecular subtype is basically based on the 
expression of relevant immunohistochemically stained receptors, and the expression of the 
proliferative marker Ki67. An illustration of immunohistochemical staining patterns for BCs 
with different receptor status is presented in figure 2. 
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The luminal BCs are so named because their molecular profile has a similar gene expression to 
the normal luminal epithelium of the breast, and they are typically estrogen receptor positive 
(ER+) and progesterone receptor positive (PR+). The luminal A tumors display high expression 
of ER, low expression of HER2 and low expression of proliferation promoting genes [26, 27]. 
Luminal B tumors exhibit ER expression at lower levels compared to the luminal A subgroup, 
they can be either HER2+ or HER2-, and they typically have a higher expression of the 
proliferation-associated protein, Ki67 [27, 28]. The luminal BCs comprise the largest subgroup 
of BCs, where the luminal B cancers account for approximately 40% of all BCs [29], thus 
making it the largest individual subgroup. Due to the higher expression of ER and the lower 
Figure 2: Representative immunohistochemical expression of ER, PR and HER2 in different subtypes of invasive BC. 
Rivenbark et al., 2013. 
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expression of proliferation markers in the luminal A tumors, this subgroup has a better 
prognosis than patients in the luminal B subgroup, with an overall survival rate 10 years after 
diagnosis of 70% vs 54%, respectively [22]. Notably, when further subgrouping the luminal B 
subgroup into luminal B/HER2+ and luminal B/HER2-, there is a significant difference in the 
overall survival rate at 10 years after diagnosis of 46% vs 54%, respectively [22]. Combined, 
however, the luminal BCs have a better prognosis compared to the non-luminal subgroups, 
which primarily is a result of their positive ER-status, hence allowing for targeted hormonal 
therapy [30]. 
The molecular subgroup HER2+ constitutes approximately 15-20% of all BC cases, where the 
HER2 gene copy number can be as high as 50, resulting in a protein overexpression close to a 
100-fold [31]. HER2 is a transmembrane receptor protein and is one of the four membrane 
receptor tyrosine kinases (RTKs) in the epidermal growth factor receptor family, first identified 
in rat neuroblastomas as a protein capable of transforming a mouse fibroblasts cell line into 
malignancy [32]. This family of receptors is important in communication between cell-cell and 
cell-stroma via signal transductors known as ligands. HER2 is a co-receptor for many ligands, 
and whilst the HER2 receptor has no known ligand of its own, the receptor forms heterodimers 
with other receptors of the HER family when activated by their ligand(s) [33]. Dysregulation 
of HER2, on both gene and protein level, is associated with a worse prognosis in both the lymph 
node-negative and lymph node-positive BC patients [34]. Adjuvant treatment of HER2+ BC 
with trastuzumab, a monoclonal antibody targeting the extracellular domain of the HER2 
protein, has proven beneficial to patient outcome, with a 34% reduction in risk of death after 
two years [35]. Currently, adjuvant treatment with trastuzumab is the standard care of treatment 
for HER2+ tumors.  
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The TN/BL subgroup is highly heterogeneous, is immunohistochemically defined as BCs not 
overexpressing HER2, and is both ER and PR negative. It is considered an especially aggressive 
subtype, in particular affecting the younger female population, and targeted therapeutic options 
are limited to clinical trials [36]. The terms TN and BL are often used as synonyms, and 
although most TN cancers are of a BL phenotype, and most tumors expressing basal-markers 
are TN, this is not always the case [37, 38]. In fact, studies have revealed that 70-90% of TN 
cancer are of a BL subtype, and 50-80% of molecular BL tumors are TN [38-40]. However, 
pooling the TN and the BL cancers into one subgroup is sensible, as they exhibit great 
similarities in that they affect younger patients, are more likely to present as interval cancers, 
and they are significantly more aggressive than tumors in other subclasses [41, 42]. 
The TNBCs account for 10-20% of all BCs, depending on the methods and thresholds used to 
evaluate ER, PR and HER2 expression [41]. There are histological subtypes which are  typically 
TN, but the TN cancers as a group lack distinctive histological characteristics [43]. With their 
expression of epidermal growth factor receptor (EGFR) together with cytokeratins 5, 14 and 
17, their genomic characteristics are similar to the normal myoepithelial (basal) cells of the 
breast [44], and interestingly, the gene expression patterns of myoepithelial mammary cells are 
similar to those found in squamous cell carcinoma of the lung [45]. 
As a result of the tumors’ negative receptor status, the TNBC patients benefit from neither 
endocrine therapy, nor trastuzumab (HER2 antagonist). The current backbone in TNBC 
management is treatment with cytotoxic chemotherapy, where TNBCs have a higher pathologic 
complete response rate when compared to hormone receptor-positive BC treated with 
neoadjuvant chemotherapy [46]. Still, however, patients harboring the TN subtype have a worse 
outcome after chemotherapy compared to patients with BC of other subtypes [44, 47]. 
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The highly heterogeneous nature of TNBC argues for personalized treatment strategies 
targeting molecular tumor-specific sites. This is further substantiated by the fact that the 
response rate of TNBC patients treated with chemotherapy is 40% or less [43]. Indeed, there 
are currently several ongoing clinical trials investigating the potential for targeted therapy for 
TNBC. These targets include, but are not limited to, the androgen receptor (phase II), the AKT-
pathway (phase II) and poly (ADP-ribose) polymerase PARP (phase III) [36]. The future of 
treating TNBCs may be brighter, as the treatment regime shifts towards more personalized, 








1.2 Non-small cell lung cancer 
Worldwide, lung cancer is the leading cause of cancer related death, and annually 1.8 million 
new lung cancer cases are reported [48]. Additionally, it is also one of the cancers with the 
highest death rate, with just short of 1.6 million people dying each year [48]. It is estimated that 
approximately 80-90% of all lung cancer cases in high-income countries are directly related to 
smoking [49], and although lung cancer incidence in men is slowly declining due to fewer 
smokers, the incidence in women continues to rise, also in Norway [50] (figure 3). 
Lung cancer is a disease that presents great challenges, as 70% of lung cancer patients have 
advanced stage at the time of diagnosis [58]. Metastases to distant organs are responsible for 
70% of all lung cancer deaths, regardless of histological subtype, and the most frequent sites 
for metastases include bone, brain, adrenal glands and liver [59]. An obvious way to decrease 
lung cancer mortality (in addition to reducing smoking in the population) is through achieving 
early diagnosis, and hence treatment, by screening programs. However, studies involving 
chest radiographs and sputum cytology for early detection did not significantly reduce lung 
Figure 3: Incidence and mortality rates in lung cancer patients from 1965-2015. 
(Adapted from www.kreftregisteret.no; Cancer in Norway 2016) 
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cancer mortality [60]. On the other hand, patients in high-risk groups participating in The 
American National Lung Screening Trial had significantly lower mortality, but there are still 
unanswered questions in regards to over-diagnosis and over-treatment [60, 61]. 
 
1.2.1 Classification 
Histologically and clinically, lung cancer is typically classified into two major groups: Small 
cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC accounts for 
approximately 15% of all diagnosed lung cancers and is a very aggressive type of cancer, 
generally observed in smokers [51].  
NSCLC is the largest group and accounts for approximately 85% of all lung cancer cases, and 
is further classified into subgroups [52]. The classification of NSCLCs was recently revised by 
the 2015 WHO Classification of Lung Tumors, and consist of squamous cell carcinoma (SCC), 
adenocarcinoma (ADC) and NSCLC not otherwise specified (NOS) [53]. ADC is the most 
common subtype observed in never-smokers [54], it typically forms glandular structures, and 
the production of mucus is sometimes observed. SCCs are typically more aggressive than 
ADCs, and can be keratinizing, non-keratinizing or display a low differentiated basaloid 
morphology, somewhat similar to that of TNBCs [45, 55]. 
Previous classification of NSCLC was based on light microscopy of hematoxylin and eosin 
stained tissue samples, and focused mainly on morphology. However, new IHC analyses have 
been applied to classify subgroups more accurately. These analyses include the thyroid 
transcription factor-1 (TTF-1), which is expressed by pneumocytes and is primarily associated 
with ADCs [53]. Similarly, the transformation-related protein 63 (p63), its isoform p40, and 
cytokeratin 5/6 (CK 5/6) are predominantly expressed in the bronchial epithelium and are 
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typically associated with SCCs [53]. On rare occasions (3% of cases), if no distinct IHC staining 
pattern is evident to indicate either ADC or SCC, then the NOS subtype is applied, and merely 
as a diagnosis of exclusion [53].  
The histological and molecular distinction between ADC and SCC is crucial when it comes to 
therapeutic decisions and to predicting the clinical course, especially for patients with 
advanced-stage disease [56]. In Norway, the recent availability of targeted treatments has 
resulted in the screening of all non-SCCs for mutations in both the EGFR and the anaplastic 
lymphoma kinase (ALK) gene at the time of diagnosis. In addition, the list of potential future 
candidates for targeted treatment of NSCLC is still growing, and include KRAS, BRAF, HER2, 








In the early era of DNA research, 3% of genes were considered to be protein-coding while the 
other 97% was considered little more than ‘junk’ DNA [58]. However, decades later, our 
understanding of the human transcriptome has changed fundamentally. Not too long ago, the 
Encyclopedia of DNA Elements (ENCODE) project reported that as much as 75% of the human 
genome is transcribed into RNA, which is a big statement to the fact that non-coding RNAs 
(ncRNAs) comprise the majority of the human transcriptome [59, 60]. The first ncRNAs were 
discovered in the 1950s, and they include the ribosomal RNA (rRNA) and the transfer RNA 
(tRNA). Since then, a vast variety of various ncRNAs have been described, where microRNAs 
(miRNAs) are the best described class of short ncRNAs [61, 62]. 
The first miRNA, named lin-4, was initially described in the transparent nematode 
Caenorhabditis elegans, and was reported as a small RNA with antisense complementarity to 
the mRNA transcript of the gene lin-14 [63]. Today, more than 2500 human miRNAs later, we 
understand that the regulation and dysregulation of miRNAs are involved in virtually all types 
of cellular processes, both benign and malignant, as miRNAs’ involvement in a vast number of 
different intracellular processes has been revealed [64-69]. 
The mature miRNA is typically 22 nucleotides in length and is normally processed by the two 
RNase III proteins Drosha and Dicer [70]. In RNA silencing, the miRNA sequence function as 
a guide by base pairing with the complementary 3’untranslated region (3’UTR) of its target 
mRNA, and when united with the AGO proteins, this ultimately results in either translational 




1.3.1 MiRNA biogenesis 
The genes encoding miRNAs are typically located within intergenic regions, but approximately 
30% of miRNA genes are positioned within introns or exons of protein-coding genes [71]. It is 
not unusual that miRNA loci are positioned in relative close proximity to each other, making a 
polycistronic transcription unit, often referred to as a miRNA cluster [72]. The miRNA cluster 
is generally subject to a common promoter region, and is hence cotranscribed. However, 
subsequent differentiated processing and regulation at the posttranscriptional level is common 
[72, 73]. The miRNA genes that reside in the introns or exons of protein-coding genes often 
share promoter with their host gene, but it has been shown that different miRNA genes can have 
several start sites for transcription, which is also the case for intragenic miRNA, whose 
promoter site can be distinct from the promoters of their host genes [74]. 
The vast majority of miRNAs are transcribed by RNA polymerase II (RNA pol II). This is 
apparent when considering the length of the primary miRNA (pri-miRNA) transcript, which is 
more than 1 kb longer than a typical RNA pol III transcript [75]. In addition, the pri-miRNA 
transcript  contains sequences of uridine residues, which terminate transcription by RNA pol 
III [76]. Transcriptional regulation of miRNAs is typically directed by various factors, like the 
transcription factors p53, MYC, ZEB1 and ZEB2, as well as epigenetic factors, like DNA 
methylation and histone modification [73, 77, 78]. 
Transcribed pri-miRNA is typically >1 kb long and forms a specific hairpin-shaped stem-loop 
secondary structure where the mature miRNA sequence is embedded. Typically, a pri-miRNA 
consists of the mature miRNA-containing stem (33-35 bp), the terminal loop, and a single-
stranded RNA segment at both the 5’ and 3’ side [73]. The nuclear maturation process of pri-
miRNA is in essence initiated by the nuclear RNase III protein Drosha in collaboration with the 
DiGeorge syndrome chromosomal region 8 (DGCR8) protein. The RNA binding protein 
15 
 
DGCR8 identifies and binds pri-miRNA and the central part of the Drosha protein. Together, 
these proteins form the Microprocessor complex, which process the 5’ and the 3’ strand of the 
pri-miRNA into an approximately 65 bp hairpin-shaped RNA structure called precursor 
miRNA (pre-miRNA) [79, 80]. The pre-miRNA is subsequently exported into the cytoplasm, 
where maturation can be completed. The export of pre-miRNA is aided by the protein exportin 
5 (EXP5), whose interaction with the GTP-binding nuclear protein RAN∙GTP forms a 
transporter complex [81]. Upon reaching the cytoplasm through the nuclear pore, the GTP is 
hydrolyzed and the pre-miRNA/EXP5/RAN∙GTP-complex is disassembled, resulting in the 
release of pre-miRNA into the cell’s cytosol [82, 83]. 
Figure 4: miRNA pathway. An illustration of the miRNA pathway from transcribed pri-miRNA to translational 
repression. Modified from He et al., 2016. 








Once the pre-miRNA is released into the cytosol, the RNase III endonuclease Dicer carries out 
the next step in miRNA maturation. Dicer recognizes the 5’ phosphate and the 3’ overhang 
close to the terminal loop, and cleaves the double stranded pre-miRNA at this site, producing a 
roughly 22 bp long RNA duplex often referred to as a miRNA:miRNA* complex [73, 76, 84]. 
There are many different factors and pathways regulating the activity of Dicer, the most 
recognized being by the TAR RNA-binding protein (TRBP). TRBP contains three double-
stranded RNA binding domains (dsRBDs) and is involved in the modulation of several pre-
miRNAs, as well as in regulating the length of mature miRNAs [85, 86]. 
Next, the miRNA:miRNA* complex is loaded into the RNA induced silencing complex (RISC) 
to finalize the miRNA maturation. The catalytic component of the human RISC complex is the 
Ago2 protein, who is essential in both binding miRNA and in releasing Dicer [87]. Ago2 is a 
protein with endonuclease activity, and it cleaves the 3’ arm of the miRNA before it is processed 
by Dicer, a course that is believed to aid in determining the mature lead miRNA strand [87, 88]. 
Selection of the miRNA lead strand is based on the relative thermodynamic stability of the two 
ends of the small RNA duplex, and the lead strand is generally the one with the more relatively 
unstable terminus at the 5ʹ side [73, 89]. In addition, the Ago2 protein selects the lead strand 
based on the first nucleotide sequence, and the lead strand presenting a U at nucleotide position 
1 is typically selected [90]. 
The Arg2, using the lead miRNA as a guide, then directs the RISC complex to downregulate 
target genes. Based on the complementarity between the 3’UTR of the target mRNA and the 
RISC incorporated miRNA, gene expression is post-transcriptionally repressed by either 
translational repression, mRNA degradation or mRNA deadenylation [70, 91]. An illustration 
of the canonical miRNA pathway is presented in figure 4 [92]. 
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1.3.2 The role of miRNAs in cancer 
Ever since the first publication describing the deletion of the miR-15 and miR-16 loci in the 
majority of samples from patients with B-cell chronic lymphocytic leukemia [93], a large 
number of papers describing dysregulation of numerous different miRNAs in a vast diversity 
of cancers has been published [94]. In general, the mechanisms involved in miRNA 
dysregulation are chromosomal abnormalities, alterations in transcriptional control, epigenetic 
changes and defects in the miRNA biogenesis [95].  
The deletion of the miR-15 and miR-16 loci was the first reported miRNA dysregulation due to 
a chromosomal abnormality (deletion). Similarly, the 5q33 region, harboring the miR-143/145 
gene cluster, is commonly deleted in lung cancer, resulting in reduced expression of both these 
miRNAs [96]. In contrast, duplication of the miR-17-92 gene cluster has been reported in both 
B-cell lymphomas and lung cancer, resulting in overexpression of these miRNAs [97, 98]. It 
has become evident that both deletions and duplications (amplifications) of specific genomic 
regions, as well as chromosomal translocations, contribute to abnormal miRNA expression. 
The expression of pri-miRNAs is subject to dysregulation similar to protein-coding genes. 
During tumorigenesis, alterations in tumor suppressors or oncogenic factors functioning as 
transcriptional activators or suppressors, will affect the expression of pri-miRNAs. One of these 
alterations involves the oncogenic miR-17-92 cluster, which is upregulated in several different 
cancers [99]. MYC stimulates expression of the miR-17-92 cluster, which in turn promotes 
tumorigenesis by regulating the post transcriptional expression of E2F1, THBS1, CTGF and 
other transcripts important for cell cycle progression and angiogenesis [94, 100]. Conversely, 
the miR-200 family is regularly reported as downregulated in human tumors. The miR-200 
family is involved in targeting important transcription factors involved in suppression of 
epithelial genes in order to facilitate the epithelial-mesenchymal transition, which is key to 
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invasion and metastasis [101]. There are many transcription factors associated with cancer that 
regulate expression of miRNAs, making transcriptional dysregulation a crucial mechanism in 
altered miRNA expression in cancer. 
Modifications of histones and DNA control the chromatin structure of the chromosome, and 
these epigenetic changes have an important role in regulating expression of both protein coding 
RNA and ncRNA. The gene promotors of miRNAs, as well as promotors for most genes, have 
a relatively high content of CpG islands, and these are frequently hypermethylated in tumor 
suppressor miRNAs, resulting in an epigenetic silencing of these miRNAs [102]. Histone 
modification is another epigenetic change, and has been reported to cooperate with DNA 
methylation to suppress the expression of tumor suppressor miRNAs in cancer [103]. Together, 
these epigenetic mechanisms play important parts in repressing tumor suppressive miRNAs in 
cancer. 
In miRNA biogenesis, the two RNase III proteins Drosha and Dicer are frequently 
downregulated in various cancers, and this downregulation is associated with poor patient 
outcome [104]. For example, the expression of DROSHA is regulated by the proto-oncogenic 
transcription factor MYC, which may lead to decreased pri-miRNA processing [105]. Also, 
downregulation of DROSHA has been reported in context with hypoxia, and this process was 
facilitated by direct binding of the hypoxia-responsive transcription factors ETS1 and ELK1 to 
the promoter of DROSHA [106]. Likewise, the expression of DICER is also subject to 
dysregulation in cancer, a process that is highly diverse. The transcription factor Tap63 
activates DICER expression by direct promotor binding to its promotor, but this transcription 
factor is frequently lost in cancer, leading to downregulation of DICER. Another pathway in 
which DICER is downregulated is through direct binding to its 3’UTR by specific miRNAs, an 
effect highly influenced by hypoxia [106, 107]. 
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2. Aims of the study 
The overall aim of this study was to explore functions and expression patterns of carefully 
selected miRNAs in breast cancer and lung cancer. To this end, we investigated expression in 
tissue samples from both breast- and lung cancer patients, alongside functional studies on 
cancer cell lines representing both organ systems. Expression of miRNA was evaluated using 
miRNA microarray, qPCR and ISH, and functional studies included experiments eligible for 
the study of cell proliferation and cell migration. 
More specifically, the objectives of the study were to evaluate expression patterns and 
functional properties of the miR-143/145 cluster in BC and NSCLC. Also, expression and 
function of the miR-126-3p, and its passenger strand, miR-126-5p, was investigated in BC 








3. Summary of results 
Paper I 
Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast 
cancer 
Vast numbers of miRNAs are dysregulated in cancer, and the miRNA cluster miR-143/145 is 
among them. In this paper, we sought to investigate the functional properties and expression of 
the miR-143/145 cluster both in vivo and in vitro in human breast cancer. For the functional 
studies we used three different BC cell lines corresponding to the major subtypes of BC: ER+, 
HER2+ and TN. In addition to analyzing expression, we also studied how the cell lines’ ability 
to proliferate and migrate/invade was affected when transfected with either miR-143 mimic, 
miR-145 mimic, or miR-143 mimic and miR-145 mimic in combination. For the in vivo part, 
the cellular and subcellular expression of miR-143 and miR-145 was evaluated in full 
histological slides from both benign and malignant breast tissue. Patient samples were stratified 
according to molecular subtype, tumor grade and receptor status, and expression patterns of 
miR-143 and miR-145 were analyzed accordingly.  
Results from a comprehensive miRNA microarray study on breast cancer tissue revealed both 
miR-143 and miR-145 to be downregulated in BC tumors when compared to benign breast 
tissue. These results were later verified by RT-qPCR. Similar, expression of both miR-143 and 
miR-145 were downregulated in all tested BC cell lines. 
In vitro, miR-143 promoted proliferation of the ER+ and the TN BC cell line, whereas having 
no significant effect on the proliferation properties of the HER2+ cell line. In contrast, all BC 
cell lines suffered proliferation inhibition when transfected with miR-145. The cotransfection 
with miR-143 and miR-145 resulted in inhibited proliferation similar to that of miR-145 alone 
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in all BC cell lines. All BC cell lines suffered inhibition of invasion when transfected with either 
miR-143, miR-145 or miR-143 and miR-145. In vivo, the expression of miR-143 and miR-145 
was lower in malignant compared to benign breast tissue, and lower in the more aggressive 
tumors with higher tumor grade, loss of ER and the basal-like phenotype. The collected ISH 
data also contributed very interesting findings regarding cellular and subcellular distribution of 
the studied miRNAs, especially for the miR-145. Staining patterns of miR-143 were primarily 
cytoplasmatic and predominantly found in luminal cells of benign breast tissue. In contrast, 
miR-145 was mainly expressed in the myoepithelial cells of benign breast tissue, and sub-
cellularly located to the nuclei. 
 
Paper II 
Different functional roles and expression of miR-126-3p and miR-126-5p in breast cancer 
cell lines and tissues 
In the literature, miR-126 is described as a tumor suppressor in various cancers, and is involved 
in regulation of metastatic processes in BCs. In this paper, we were interested in investigating 
expression and functional properties of both the miR-126-3p and its passenger strand, miR-
126-5p. The study explored the effects of transfecting miR-126-3p mimic, miR-126-5p mimic, 
or miR-126-3p mimic and miR-126-5p mimic in combination on proliferation and invasion in 
BC cell lines representing the major subtypes of BC. Expression of miR-126-3p and miR-126-
5p in tissue samples were investigated using in situ hybridization and tissue miRNA 
microarrays and PCR.  
Results from the miRNA microarray revealed both miR-126-3p and miR-126-5p to be 
downregulated in BC tumors when compared to benign breast tissue. Results were verified by 
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qPCR. Likewise, expression of both miR-126 strands were downregulated in all our tested BC 
cell lines when compared to the non-cancerous breast cell line MCF-10A. Transfection of miR-
126-3p resulted in decreased proliferation and invasion in all BC cell lines. Transfection of 
miR-126-5p decreased proliferation in the ER+ and the HER2+ BC cell lines, whereas having 
a strong opposite effect in the TN BC cell line, dramatically increasing proliferation potential. 
In vivo, expression of miR-126-5p was significantly higher in high grade tumors and in stroma 
and tumor cells of luminal B, HER2+ and TN tumors when compared to luminal A tumors. In 
addition, both miR-126 strands were downregulated in lymph node positive BCs when 
compared to tumors with no nodal involvement. 
 
Paper III 
A gender specific improved survival related to stromal miR-143 and miR-145 expression 
in non-small cell lung cancer 
In addition to the BC cohort (paper I), the miRNA cluster miR-143/145 was investigated in a 
large retrospective study including 553 NSCLC patients. Tissue was collected from primary 
lung tumors and metastatic lymph nodes, and tissue microarrays were subsequently constructed 
from these. Functional studies to evaluate proliferation and migration after transfection of either 
miR-143 mimic, miR-145 mimic, or miR-143 mimic and miR-145 mimic in combination, were 
performed using different NSCLC cell lines representing adenocarcinomas, squamous cell 
carcinomas and large cell carcinomas. Expression of miR-143 and miR-145 in tissue samples 
was investigated using in situ hybridization and tissue miRNA microarrays.  
Expression of both miR-143 and miR-145 was downregulated in all NSCLC cell lines included 
in this study. In contrast, ISH-results from patient samples demonstrated significantly increased 
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expression of miR-143/miR-145 in tumor cells and adjoining stromal cells when compared to 
non-malignant tissue. Migration studies were performed on the NSCLC cell lines representing 
adenocarcinoma and large cell carcinoma. Both cell lines displayed a notable decrease in 
migration potential when transfected with either miR-143 or miR-145. Proliferation was 
evaluated in NSCLC cell lines representing adenocarcinoma, squamous cell carcinoma and 
large cell carcinoma. Both the adenocarcinoma cell line and the large cell carcinoma cell line 
experienced proliferation inhibition when transfected with either miR-143, miR-145, or miR-
143 and miR-145 in combination. In contrast, the squamous cell carcinoma cell line displayed 
increased proliferation when transfected with miR-143, whilst displaying inhibition of 
proliferation when transfected with miR-145. When combining miR-143 and miR-145, the 
proliferation rate of the squamous cell carcinoma cell line was not significantly different to the 
negative control. In vivo, expression of the miR-143/145 cluster was found to correlate with 
expression of several sex steroid hormone receptors, including progesterone receptor, androgen 
receptor and estrogen receptor beta. In addition, stromal expression of miR-143 was an 
independent positive prognostic factor in female patients in both univariate and multivariate 
analysis, whereas stromal expression of miR-145 was associated with improved disease specific 




4. General discussion 
The main focus of this work has been to investigate functional properties and expression 
patterns of selected miRNAs in breast cancer tissue. In paper III we investigate the same 
miRNAs as in paper I, but in NSCLC. Results for each paper are discussed within the 
respective papers. In the first part of the discussion (4.1), selected materials and methods will 
be briefly presented and discussed, and in the second part (4.2) the major findings in each paper 
will be discussed. 
 
4.1 Materials and methods 
4.1.1 Patient cohorts 
Patients in the BC cohort were collected from the NOWAC postgenome cohort [108], and 
included participants diagnosed with BC during the years 2004-2010. A total of 102 BC surgery 
specimens and 38 benign breast specimens were included in the miRNA microarray, and the 
data from the miRNA microarray analysis were used in the planning and design of papers I 
and II. The histological grading was based on the modified criteria by Elston and Ellis [109], 
and the molecular subtyping of tumors were based on the expression of ER, PR, HER2 and 
Ki67 in consensus with guidelines provided by the St Gallen International Expert Consensus 
and previous publications [29, 110]. 
The large NSCLC cohort, which is a part of paper III, comprises 553 resected patients with 
stage I-IIIB NSCLC. The cohort includes patients who underwent surgical resection at the 
Nordland Central Hospital (NS), Bodø and the University Hospital of North Norway (UNN), 
Tromsø from 1990-2011 [111, 112], and includes complete medical records with follow-up 
data up until October 1, 2013 [113]. 
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The most common histological subtype of NSCLC has shifted during the last years from SCC 
towards ADC. This shift contributes to our data being not quite representative of the current 
situation, as the SCC subtype had a higher frequency in the early material (1990-2004), which 
contains 335 of the 553 patients in the NSCLC cohort [111, 112]. The enrollment of patients 
and the collection of clinical data used in this study was done over a time period spanning more 
than 20 years. During this period, there have been several alterations in how lung cancer was 
treated, with the most important one being the implementation of adjuvant chemotherapy in 
2005. Moreover, criteria for diagnosing and subtyping NSCLC have also changed during the 
follow up period. The changes in treatment regimens and criteria for diagnosing and subtyping 
that have been implemented since the start of data collection present a challenge for this 
retrospective study, as the longitudinal data may not have been treated adequately 
homogenously, resulting in skewed results. However, to counter any discrepancies due to 
updated criteria and to minimize test-retest variations, all tumor material was systematically 
examined by an experienced pathologist whenever new criteria for NSCLC classification were 
applied. 
 
4.1.2 Tissue microarray 
The process of constructing a tissue microarray (TMA) involves systematically transferring 
cylinders of small representative tissue from a ‘donor’ block, usually a whole-tissue section 
(WTS) block, into an empty ‘recipient’ paraffin block [114]. One ‘recipient’ block may hold 
several hundred cores, allowing several samples from numerous patients in the same ‘recipient’ 
block [115]. 
Compared to WTSs, TMAs saves both time and tissue, as one slide containing TMAs can hold 
close to 800 cores. Another very important advantage of using TMAs, is the elimination of 
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batch-to-batch variability. To analyze the same amount of samples using WTSs, one would 
have to prepare slides from hundreds of patients, and the staining process would have to be 
performed in numerous batches, greatly increasing the chance for batch-to-batch variability 
[116]. The pathologist(s) that would subsequently evaluate and analyze the samples to identify 
the relevant tumor compartments, would be facing a very time consuming task, complicating 
the standardization of staining. 
In regards to challenges using TMA, the question of whether a 0.6-1.0 mm core is representative 
for the heterogeneity of the total tumor is often raised. Studies have, however, revealed that 
there can be a correlation of more than 90% when comparing the expression of certain 
biomarkers in TMA and WTS [117, 118], and a recent study provides additional evidence of 
reliability in determining biomarkers using TMA when using more than one tissue core [119]. 
It is, however, important to also consider the limitations of WTS, as one single WTS contains 
a small fragment of the total tumor volume, hence representing a small part of the tumor, and 
may not itself be representative for large heterogenic tumors. 
 
4.1.3 Immunohistochemistry 
IHC is a method for the detection of antigens within cells or tissue sections (usually WTSs or 
TMAs) using specific antibodies against the antigen of interest. Next, the antibody-antigen 
complex is visualized by staining. This is a versatile technique, and can be used to assess the 
expression of numerous antigens, including proteins, amino acids and infectious agents. IHC is 
an important tool in routine diagnostics, as well as in basal research [120]. 
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The advantages of IHC are many, and include cost effectiveness and in situ assessment of 
distribution and localization of cellular components of interest. It is a well-established method 
around the world, and IHC analysis can be performed on archived tissue, decades old. 
Factors contributing to the challenges of IHC include adequate fixation, tissue processing and 
antigen retrieval. If tissues are not adequately fixated, decomposition of tissue and its markers 
may occur, and insufficient antigen retrieval may contribute to false negative results. Other 
analytical factors include selecting antibody with sufficient specificity, antibody concentration 
for adequate visualization, incubation conditions, and selection of secondary antibodies and 
mode of detection. 
 
4.1.4 In situ hybridization 
ISH is a method used to detect specific nucleotide sequences, like DNA and RNA, in tissue 
samples or in individual cells. A probe with a specific nucleotide sequence is hybridized to its 
target RNA or DNA, and subsequently visualized microscopically. 
A great advantage when using ISH for the detection of miRNAs, is the visualization of both 
expression levels and the ability to pinpoint cellular localization. However, miRNAs are small 
in size, the sequence between related miRNAs may be very similar, resulting in unspecific 
hybridization, and they may be tissue specific. Other challenges are similar to those for IHC, 
and include probe specificity, probe concentration, incubation conditions and mode of 
detection. Probe specificity is important to avoid unspecific hybridization (false positive), 




4.1.5 Human cell lines 
Human immortalized cancer cell lines are widely used as a substitute for primary cells to 
investigate the biology of human cancers. They are cost effective, easy to use, they divide 
practically eternally, hence producing an unlimited supply of material, and they bypass ethical 
concerns often associated with animal studies. In addition, they comprise a very pure population 
of cells, absent of stromal and immune cells, contributing to consistency and reproducibility of 
results. However, this also produces a challenge, as cell lines are cultivated in absence of a 
normal tumor microenvironment, lacking the stromal compartment. Also, cell lines are highly 
manipulated and their original phenotype, functions and responsiveness may, to a great extent, 
have been lost [121]. Additionally, high passage numbers can inflict both genotypic and 
phenotypic variations, and genetic drift may over time cause heterogeneity in cell cultures 
[121]. 
It is important to realize that cell lines do not mirror primary cells, which in turn do not mirror 
source tissue either, and caution should be made when/if conclusions are drawn from cell line 
experiments. It is also important to recognize that both primary cells and cell lines are usually 
cultured in the absence of their normal environment, again urging for the use of caution when 




4.2 Discussion of main results 
4.2.1 Paper I 
In the first paper we present functional properties and expression patterns of the miRNA cluster 
miR-143/145 in BC. The findings are based on results from functional studies, miRNA 
microarray, RT-qPCR and ISH. A miRNA cluster is miRNAs whose genes are localized in 
close proximity to each other on the DNA, resulting in their simultaneous transcription under 
the control of a common promotor. The correlation in expression between miR-143 and miR-
145 was highly significant (R=0.88, p<0.001), suggesting their cotranscription. 
We found the miR-143/145 cluster to be significantly downregulated in tumor cells when 
compared to benign cells, both in tissue samples collected from the BC cohort and in BC cell 
lines. Downregulation of the miR-143/145 cluster has been previously published for both BC 
and other cancer tissues [113, 122-126], but together with miRNA microarray and RT-qPCR, 
our study also verified expression in BC by ISH. 
Results from the miRNA microarray indicated that expression of the miR-143/145 cluster was 
higher in ER+ tumors than in ER- tumors, and this result was later verified by RT-qPCR (paper 
I, table 4). Partly due to their sensitivity to endocrine therapy targeting the ER, ER+ BCs are 
generally considered among the least aggressive subtypes. In fact, increased expression of both 
miR-143 and miR-145 was observed consistently in the least aggressive subtypes (paper I, 
tables 3 and 5). This finding is in line with previous studies describing miR-143 and miR-145 
as tumor suppressor miRNAs [127-129]. 
Functions of miRNAs are complex, and not yet fully understood, as is exemplified by 
publications reporting adverse effects of miR-143 and miR-145. Dimitrova et al. reported the 
stromal expression of miR-143 and miR-145 to stimulate neoangiogenesis, and in turn facilitate 
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tumor expansion in the lung [130]. Also, Donnarumma et al. reported increased levels of miR-
143 in exosomes from cancer associated fibroblasts, and that exosome mediated delivery to BC 
cells could promote further BC progression [131]. 
Results from the functional studies performed for paper I were interesting and somewhat 
surprising. The miR-143, which is conventionally considered a tumor suppressor [128, 132, 
133], displayed evidence of tumor promoting characteristics. The functional studies in paper I 
included three different BC cell lines, representing the major subtypes of BC. When transfecting 
these with the miR-143 mimic, both the ER+ and the TN BC cell line experienced increased 
proliferation. Proliferation in the HER2+ cell line did not significantly change from the negative 
control after transfection with the miR-143 mimic. These findings confirm the presence of a 
dualism in the function of miRNAs, and that environment and cellular context may be more 
important than expected. 
Interestingly when considering the proliferation experiments, the miR-143 mimic had 
inhibitory effect on the cells’ ability to invade in all three BC cell lines. In addition, all three 
BC cell lines suffered inhibition of both proliferation and invasion when transfected with the 
miR-145 mimic. The inhibitory effect on proliferation presented as very potent (paper I, 
figures 2a-c), and these results are in accordance with most of previous publications on miR-
145 [134-139]. Cotransfecting miR-143 and miR-145 in equal concentration, resulted in an 
inhibition of both proliferation and invasion in all three BC cell lines, which is in line with 
previous publications [140-142]. The magnitude of the effect was similar to that of the cells 
transfected with miR-145 alone. This translates into two deductions: 1) the proliferation 
promoting properties of miR-143 in the ER+ and the TN BC cell lines were not able to 
significantly halt the inhibitory effects of miR-145, and 2) the cotransfection of miR-143 and 
miR-145 did not in synergy contribute to significantly lower the cells invasive potential when 
32 
 
compared to cells transfected with either miR-143 or miR-145 alone (paper I, figure 2d). 
Different results in different BC cell lines may be explained by the target genes that are active 
in operating the oncogenic phenotype at any given time, and the miRNAs that are there to 
regulate them. 
A very interesting finding in paper I was the subcellular miR-145 distribution in the nuclei of 
myoepithelial cells (paper I, figure 7). Mature miRNAs located to the nucleus are gaining 
more and more interest, and in a very recent review by Liu et al. they summarize existing 
evidence of nuclear miRNAs [143]. The list of nuclear mature miRNAs is ever growing, and a 
relevant selection is presented in table 1. 
In addition to nuclear enrichment of mature miRNAs, which presence is in divergence to earlier 
beliefs, new and surprising functions of miRNAs are also starting to emerge. Recent 
publications have reported that nuclear miRNAs probably are involved in upregulation of 
transcription via interactions between miRNAs and gene promotors and enhancers [144]. 
Interestingly, Xiao et al. recently published a research article describing miRNAs as epigenetic 
gene activators, and that a subset of miRNAs is capable of activating transcription by means of 
association with active genetic enhancers [145]. Further, they demonstrated that miR-24-1 
function as an alternative mediator for transcriptional gene activation by facilitating the 




Table 1: Profiling of nuclear microRNAs. Adapted from [143]. 
Cell line Method Result 
Human nasopharyngeal 
carcinoma (NPC) 5-8F cell line 
Deep sequencing 
Among 339 nuclear and 324 
cytoplasmic miRNAs, 300 of them 
overlap. 






The overall average of nuclear ratio 
of miRNAs is 0.471 ± 0.15. 
MiR-16, miR-19b, miR-200b, miR-
222, miR-29b, miR-29c are highly 
expressed in the nucleus. 
MiR-19b, miR-195 are highly 




In situ Hybridization 
11 miRNAs are highly expressed in 
the nucleolus. 
MiR191, miR-484, miR-574-3p and 
miR-193b are highly expressed in the 
nucleolus 
The human breast cancer cell 
line MCF-7, MDA-MB-231 and 
the human mammary epithelial 
cell line MCF-10A (normal 
breast cells) 
Microarray 
Nuclear/cytoplasmic ratios of 
numerous miRNAs vary considerably 






4.2.2 Paper II 
Based on results from miRNA microarray on the BC cohort and previous work performed by 
our research group, we wanted to investigate the miR-126. Downregulation of miR-126 is 
previously reported in malignant breast tissue, and is associated with metastatic progression in 
BC cells, mainly through upregulation of key functions such as cell proliferation, migration, 
and survival [146, 147]. In order to gain more insight into functions and expression, we decided 
to include the passenger strand, miR-126-5p, into our inquiry.  
We found endogenous expression of both miR-126-3p (lead strand) and miR-126-5p (passenger 
strand) to be significantly downregulated in tumor cells when compared to benign cells, both 
in tissue samples collected from the BC cohort and in BC cell lines representing the major 
subtypes of BC: ER+, HER2+ and TN. 
Endogenous expression of miR-126-3p is considered to be tumor suppressive [148-151], and 
this is supported by our findings in the functional experiments, where all three BC cell lines 
suffered both reduced proliferation and reduced invasive capacity when transfected with the 
miR-126-3p mimic (paper II, figures 3 and 4). Surprisingly, the TN BC cell line experienced 
a very potent increase in proliferation when transfected with miR-126-5p, whilst the ER+ and 
the HER2+ BC cell lines suffered inhibition of proliferation when transfected with the same 
miRNA. Invasion potential was also increased in the TN BC cell line when transfected with 
miR-126-5p, but the magnitude of the response was not as obvious as it was for the proliferation 
experiment. These findings are not in line with previous publications, where the passenger 
strand, miR-126-5p, is reported to work in synergy with the lead strand, miR-126-3p, to 
facilitate a tumor suppressor phenotype [151, 152]. However, there are several reports 
supporting our findings in the TN BC cell line, and they put miR-126-5p in association with 
tumor supporting properties such as drug resistance and poor prognosis in acute myeloid 
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leukemia (AML) patients [153], promotion and protection of endothelial proliferation by 
inhibition of Dlk1 and SetD5 [154, 155], and induction of proliferation and angiogenesis in 
non-tumorigenic cells via the PI3K/AKT and MAPK/ERK pathways [156]. Other pathways 
described in association with miR-126-5p and enhanced tumor progression, include the 
NOTCH pathway, the Akt signaling pathway and the IGF-1 signaling pathway [157-159]. 
Expression analysis using TMA revealed that stromal levels of miR-126-5p were significantly 
associated with both molecular subtype and histological grade, and the highest levels of miR-
126-5p were found in the more aggressive subtypes of BC. In this context it is also relevant to 
point out the correlation between miR-126-5p and the proliferation marker Ki67, at R=0.24, 
p=0.055.  Although not statistically significant at the p≤0.05 level, it is worth considering in 
this setting. In the clinical tissue material analyzed by microarray and RT-qPCR, expression of 
miR-126-3p and miR126-5p was lower in BCs with nodal involvement (paper II, figure 5). 
As previously described, miR-126 is associated with metastases, and has been demonstrated as 
a negative regulator of the metastatic process in BC, in part by suppressing tumor growth in 
vitro using highly metastatic BC cell lines [146]. Knockdown of miR-126 has also been proven 
to lead to formation of metastases with high blood vessel density due to increased recruitment 
of endothelial cells to the metastatic cells [160].  
The passenger strands of miRNAs are typically degraded after processing, and are consequently 
less abundant compared to their lead strand [161], and this is also evident in our study when 
analyzing results from microarray and PCR. Interestingly, when comparing endogenous levels 
of lead strand miRNA with endogenous levels of passenger strand miRNA in the non-cancerous 
breast cell line MCF-10A, the ER+ BC cell line, the HER2+ BC cell line and the TN BC cell 
line, we discovered an incremental shift in the miR-126-3p/miR-126-5p expression pattern, 
revealing miR-126-5p to be the more abundant strand in the TN BC cell line (paper II, figure 
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2). It is possible that mechanisms responsible for targeting the passenger strand for degradation 
are either corrupted, or in some way modified, allowing the accumulation of the passenger 
strand (paper II, figure 8). Consequently, a larger part of the mature passenger strand is eligible 
to interact with the RISC-complex to exhibit a more potent biological response in the TN BC 
cell line, which represents the most aggressive BC subtype. 
There was a strong link between molecular subtype, tumor grade and expression of miR-126-
5p in the tumor stromal compartments. Several studies have described considerable crosstalk 
between tumor and stroma via exosomal transfer of miRNAs [162-164] where microvesicles 
containing miRNAs derived from cancer cells convert fibroblast into cancer associated 
fibroblasts (CAFs) with tumor-promoting properties. Together with functional studies on miR-
126-5p, the increased expression in stroma of more advanced BCs tells an interesting story. 
This work has provided valuable insight into the duplicity of miRNA function, emphasized by 
mature miR-126 having both potent tumor suppressor and tumor driver functions with opposite 
effects of the two different miR-126 strands in TN BC.  
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4.2.3 Paper III 
Herein, we present results on functional studies, expression patterns, and prognostic 
significance in regards to the same miRNA cluster as in paper I, namely the miR-143/145 
cluster. The work in this paper was performed on a NSCLC cohort comprising 553 patients and 
NSCLC cell lines. My involvement in this work was primarily on the design and 
implementation of the functional studies, and the subsequent interpretation and discussion of 
the results obtained from these studies. 
The results from this work revealed stromal expression of miR-143 to be a positive prognostic 
marker in the female population, and it was also demonstrated that stromal expression of miR-
145 is a positive prognostic marker in the male population. Previous publications have reported 
comparable findings, where low expression of miR-145 was associated with poor outcome in 
NSCLC and prostate cancer [165, 166]. However, there are reports of miR-143/145 expression 
having a negative impact on survival for patients with esophageal cancer [167] and bladder 
cancer [168], suggesting that impact of the expression patterns is tissue-specific. There are 
indications implying that expression of certain miRNAs may be gender specific, in addition to 
tissue-specific, and Duttagupta et al. have observed a subset of miRNAs to be differentially 
expressed in men and women [169]. This is interesting, and in line with our results, where 
stromal expression of miR-143 was associated with positive prognosis in women, and stromal 
expression of miR-145 was associated with positive prognosis in men. 
The functional experiments were performed on NSCLC cell lines representing adenocarcinoma, 
squamous cell carcinoma and large-cell lung cancer. Cell lines were transfected with either 
miR-143 mimic, miR-145 mimic or miR-143 and miR-145 in equal concentrations. All cell 
lines suffered a significant loss in their capacity to both proliferate and migrate when introduced 
to miR-145. The adenocarcinoma cell line and the large-cell lung cancer cell line displayed 
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similar behavior when introduced to either miR-143 alone, or miR-143 and miR-145 in 
combination and in equal concentrations, although the effect was less prominent for the miR-
143 transfected cells. When the squamous cell carcinoma cell line was transfected with miR-
143, the proliferation was significantly increased, indicating miR-143 to promote tumor growth 
in this cell line. This is a very interesting observation when considering the results from the BC 
study on miR-143 and miR-145. In paper I we demonstrated that miR-143 was a potent tumor 
promoting factor in the ER+ and the TN BC cell lines (paper I, figures 2a and 2c). We have jet 
to explain why miR-143 has this effect on these cell lines, but it is noteworthy that basal cells 
and squamous cells share many cellular signatures [45, 55]. It is possible that the proliferation 
promoting properties of miR-143 in these two cell lines from different organs are a direct result 
of their cellular similarities, perhaps arguing for cell-type specific miRNAs rather than, or in 
addition to, tissue-specific miRNAs. Unfortunately, we were not able to get the squamous lung 
cancer cell line to migrate, so there are no results for this experiment. It would have been 
interesting to observe if the miR-143 has an inhibitory effect on migration in the squamous cell 
lung carcinoma cell line, like it had in the TN BC cell line, or if it would promote migration as 
it promotes proliferation.  
As we observed for BC cell lines in paper I, the miR-143/145 cluster has a two-faced function 
in NSCLC cell lines as well, probably ascribed to cellular context. In order to increase our 
understanding into this duplicity, future experiments should focus on deciphering cellular 
pathways and miRNA targets in cells with different subtype, but within the same tissue, and 




5. Conclusions and future perspectives 
The discovery of miRNAs in the early 1990s was groundbreaking, and a MeSH search (medical 
subject heading search) today, revealed close to 60 000 entries regarding miRNAs in the 
PubMed database. In the majority of publications their described function appears to be pretty 
obvious: To act as post-transcriptional inhibitors of translation, targeting specific mRNAs via 
interactions with endonucleases. Today, however, we have come to realize that the actual 
picture is far more complicated. New pathways and mechanisms of action are frequently being 
described for both well-known and newly discovered miRNAs. Very recently (August 2018), 
Dragomir et al. published a SnapShot in Cell, describing unconventional functions of miRNAs, 
including miRNAs directly activating transcription and miRNAs coding for proteins [170]. 
These are modes of action quite opposite to the central/old dogma of miRNA biogenesis and 
function, and will likely maneuver future miRNA research into new directions. 
The main focus of this thesis has been on investigating functions and tissue expression of 
selected miRNAs identified as dysregulated in BC. We have determined that the miR-143/145 
cluster generally function as a tumor suppressor, which is in accordance with the general 
consensus, but that this function is dependent on (at least) cellular context. The functional 
dualism observed for the miR-143 in both BC cell lines and NSCLC cell lines, emphasizes the 
need for more specific research into pathways and functions of miRNAs. Adding to this story, 
are the results from the paper describing miR-126. Again, we encounter results contradicting 
the general consensus, and again we observe a dualism in function which is unsuspected. 
One of the major questions of the future is whether or not miRNAs can be effective players in 
targeted therapy, e.g. as miRNA replacement therapy in cancer treatment. Indeed, interesting 
research has depicted certain miRNAs to prevent development of drug resistance when used in 
multi-targeted treatment [171, 172], and the first miRNA treatment eligible for clinical trial, 
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MesomiR-1, quite recently completed phase I, and preliminary results are promising [173]. But 
as this thesis accentuates, caution should be exercised when navigating the miRNA landscape 
in search for new therapeutics, as their functional duality may become a concern. 
Hopefully, the future development of new technologies will help shed light on the complex role 
of miRNA function in human cells. It is my sincere belief that, guided by miRNAs, the future 
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